TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Brief Summary: The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.


Options:
A: Arm Label: Low dose Argatroban + rt-PA (alteplase); Type: EXPERIMENTAL; Interventions: Drug: Low Dose Argatroban, Drug: rt-PA (alteplase) | Arm Label: High dose Argatroban + rt-PA (alteplase); Type: EXPERIMENTAL; Interventions: Drug: High Dose Argatroban, Drug: rt-PA (alteplase) | Arm Label: rt-PA (alteplase); Type: ACTIVE_COMPARATOR; Interventions: Drug: rt-PA (alteplase) | Intervention Type: DRUG; Name: Low Dose Argatroban; Assigned to Arm(s): Low dose Argatroban + rt-PA (alteplase) | Intervention Type: DRUG; Name: High Dose Argatroban; Assigned to Arm(s): High dose Argatroban + rt-PA (alteplase) | Intervention Type: DRUG; Name: rt-PA (alteplase); Assigned to Arm(s): High dose Argatroban + rt-PA (alteplase), Low dose Argatroban + rt-PA (alteplase), rt-PA (alteplase)
B: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
C: Arm Label: Early start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Early start of NOAC | Arm Label: Late start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Late start of NOAC | Intervention Type: OTHER; Name: Early start of NOAC; Assigned to Arm(s): Early start of NOAC | Intervention Type: OTHER; Name: Late start of NOAC; Assigned to Arm(s): Late start of NOAC
D: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Teams Advancing Patient Experience: Strengthening Quality (TAPESTRY): A Randomized Controlled Trial Using the Health TAPESTRY Approach to Care for Older Adults
Brief Summary: Health TAPESTRY is a delayed intervention pragmatic randomized control trial promoting interprofessional team collaboration, facilitating connection to the community through system navigation and trained community volunteers, enhancing communication and improving care through the use of technology to better understand and assist older adult patients in achieving their health goals and to enable them to have optimal aging.


Options:
A: Arm Label: Patient Group 1; Type: EXPERIMENTAL; Interventions: Other: Health TAPESTRY Intervention | Arm Label: Patient Group 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Health TAPESTRY Intervention; Assigned to Arm(s): Patient Group 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Patient Group 2
B: Arm Label: Comprehensive drug review; Type: EXPERIMENTAL; Interventions: Other: Comprehensive drug review | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive drug review; Assigned to Arm(s): Comprehensive drug review
C: Arm Label: Control arm= usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: OTHER; Interventions: Other: intervention | Intervention Type: OTHER; Name: intervention; Assigned to Arm(s): Intervention arm
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Mobile Geriatric Team intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mobile Geriatric Team intervention; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Brief Summary: This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
B: Arm Label: natalizumab; Type: EXPERIMENTAL; Interventions: Drug: natalizumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: natalizumab, Drug: Placebo | Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): Placebo, natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Laquinimod 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod 0.6 mg, Laquinimod 1.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Laquinimod 0.6 mg
D: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Brief Summary: This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.


Options:
A: Arm Label: fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: fingolimod 0.25mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: glatiramer acetate 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate | Intervention Type: DRUG; Name: fingolimod; Assigned to Arm(s): fingolimod 0.25mg, fingolimod 0.5 mg | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): glatiramer acetate 20 mg
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Laquinimod 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod 0.6 mg, Laquinimod 1.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Laquinimod 0.6 mg
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Placebo | Arm Label: Cohort 3.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 30mg, Drug: Placebo | Arm Label: Cohort 3.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 30mg, Drug: Placebo | Arm Label: Cohort 4.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 4.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 5.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 5.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 60mg | Intervention Type: DRUG; Name: Ofatumumab 3mg; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3.2, Cohort 4.2, Cohort 5.2 | Intervention Type: DRUG; Name: Ofatumumab 30mg; Assigned to Arm(s): Cohort 3.1, Cohort 3.2 | Intervention Type: DRUG; Name: Ofatumumab 60mg; Assigned to Arm(s): Cohort 4.1, Cohort 4.2, Cohort 5.1, Cohort 5.2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3.1, Cohort 3.2, Cohort 4.1, Cohort 4.2, Cohort 5.1
D: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Drug: alemtuzumab GZ402673 | Intervention Type: DRUG; Name: alemtuzumab GZ402673; Assigned to Arm(s): Alemtuzumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Contribution of Ultrasound for Peripheral Intravenous Catheter Placement by Intensive Care Nurses
Brief Summary: Peripheral intravenous access is a major intervention in patients admitted to an intensive care unit. Systematically performed by nurses, it is also an essential intervention when the central venous access has to be removed. However, in the intensive care unit, patient centered-characteristics such as previous history of intravenous drug abuse, obesity, history of multiple vascular punctures or fluid overload most often affect the success rate of this procedure. For these patients, failure consequences are numerous: 1) delayed discharge from the intensive care unit, 2) increased pain and dissatisfaction, 3) increased incidence of catheter-related bloodstream infections. The use of ultrasound has gained increasing popularity particularly for obtaining central venous access. We hypothesize that, among trained nurses, ultrasound-guided peripheral venous access could represent an attractive alternative compared to the traditional anatomical method in order to increase the success rate.


Options:
A: Arm Label: Grade 1 Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 2A Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 2b Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 3 Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Intervention Type: OTHER; Name: IV placement using ultrasound guidance vs traditional method; Assigned to Arm(s): Grade 1 Vein Visualization, Grade 2A Vein Visualization, Grade 2b Vein Visualization, Grade 3 Vein Visualization
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Device: Ultrasound-guided peripheral venipuncture | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional peripheral venipuncture | Intervention Type: DEVICE; Name: Ultrasound-guided peripheral venipuncture; Assigned to Arm(s): Intervention group | Intervention Type: DEVICE; Name: Conventional peripheral venipuncture; Assigned to Arm(s): Control group
C: Arm Label: Classical method of peripheral venous catheterization; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Ultrasound guided peripheral venous catheterization; Type: EXPERIMENTAL; Interventions: Device: Vascular ultrasound system | Intervention Type: DEVICE; Name: Vascular ultrasound system; Assigned to Arm(s): Ultrasound guided peripheral venous catheterization
D: Arm Label: Midline; Type: ACTIVE_COMPARATOR; Interventions: Device: Midline | Arm Label: Conventional; Type: ACTIVE_COMPARATOR; Interventions: Device: PVC and/or PICCline | Intervention Type: DEVICE; Name: PVC and/or PICCline; Assigned to Arm(s): Conventional | Intervention Type: DEVICE; Name: Midline; Assigned to Arm(s): Midline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Basal Cell Carcinoma Using a One-stop-shop With Reflectance Confocal Microscopy: a Randomized Controlled Multicenter Trial
Brief Summary: The purpose of this study is to assess the efficacy and safety of the one-stop-shop concept, using real-time in vivo reflectance confocal microscopy as diagnostic tool, prior to surgical management of new primary basal cell carcinoma


Options:
A: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
B: Arm Label: RCM-OSS procedure; Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): RCM-OSS procedure | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): RCM-OSS procedure, Standard of care procedure
C: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
D: Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Arm Label: Reflectance confocal microscopy (RCM); Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): Reflectance confocal microscopy (RCM) | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): Reflectance confocal microscopy (RCM), Standard of care procedure

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Basal Cell Carcinoma Using a One-stop-shop With Reflectance Confocal Microscopy: a Randomized Controlled Multicenter Trial
Brief Summary: The purpose of this study is to assess the efficacy and safety of the one-stop-shop concept, using real-time in vivo reflectance confocal microscopy as diagnostic tool, prior to surgical management of new primary basal cell carcinoma


Options:
A: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
B: Arm Label: RCM-OSS procedure; Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): RCM-OSS procedure | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): RCM-OSS procedure, Standard of care procedure
C: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
D: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease (ESRD) (SPin-D) Trial
Brief Summary: The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.


Options:
A: Arm Label: Spirnolactone; Type: EXPERIMENTAL; Interventions: Drug: spironolactone | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): Spirnolactone
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: spironolactone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Spironolactone 12.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Spironolactone 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Spironolactone 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Placebo, Spironolactone 12.5 mg, Spironolactone 25 mg, Spironolactone 50 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does the Addition of Virtual Reality Training to a Standard Program of Inpatient Rehabilitation Improve Sitting Balance Ability and Function After Stroke? A Blinded Randomized Controlled Trial.
Brief Summary: The purpose of this study is to determine if the addition of 10 to 12 sessions of sitting balance exercises using virtual reality training will provide additional gains in balance ability and function over standard inpatient rehabilitation in stroke patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: robot therapy (ARMin) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional therapy | Intervention Type: DEVICE; Name: robot therapy (ARMin); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: conventional therapy; Assigned to Arm(s): 2
B: Arm Label: VRT; Type: EXPERIMENTAL; Interventions: Other: virtual reality training | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: control | Intervention Type: OTHER; Name: virtual reality training; Assigned to Arm(s): VRT | Intervention Type: OTHER; Name: control; Assigned to Arm(s): control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: LapSimGyn training until expert proficiency level is reached | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional clinical education | Intervention Type: BEHAVIORAL; Name: LapSimGyn training until expert proficiency level is reached; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Traditional clinical education; Assigned to Arm(s): 2
D: Arm Label: Virtual Reality Therapy; Type: EXPERIMENTAL; Interventions: Other: Virtual Reality | Arm Label: Traditional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional Therapy | Intervention Type: OTHER; Name: Virtual Reality; Assigned to Arm(s): Virtual Reality Therapy | Intervention Type: OTHER; Name: Traditional Therapy; Assigned to Arm(s): Traditional Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does the Addition of Virtual Reality Training to a Standard Program of Inpatient Rehabilitation Improve Sitting Balance Ability and Function After Stroke? A Blinded Randomized Controlled Trial.
Brief Summary: The purpose of this study is to determine if the addition of 10 to 12 sessions of sitting balance exercises using virtual reality training will provide additional gains in balance ability and function over standard inpatient rehabilitation in stroke patients.


Options:
A: Arm Label: Trunk training; Type: EXPERIMENTAL; Interventions: Other: Trunk training | Arm Label: Cognitive exercises; Type: SHAM_COMPARATOR; Interventions: Other: Cognitive exercises | Intervention Type: OTHER; Name: Trunk training; Assigned to Arm(s): Trunk training | Intervention Type: OTHER; Name: Cognitive exercises; Assigned to Arm(s): Cognitive exercises
B: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional physiotherapy | Arm Label: Target group; Type: EXPERIMENTAL; Interventions: Other: Conventional physiotherapy, Other: Techniques based on patients' functional level were added. | Intervention Type: OTHER; Name: Conventional physiotherapy; Assigned to Arm(s): Control group, Target group | Intervention Type: OTHER; Name: Techniques based on patients' functional level were added.; Assigned to Arm(s): Target group
C: Arm Label: Measurements and T-chair training; Type: EXPERIMENTAL; Interventions: Device: T-chair | Arm Label: Measurements; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: T-chair; Assigned to Arm(s): Measurements and T-chair training
D: Arm Label: VRT; Type: EXPERIMENTAL; Interventions: Other: virtual reality training | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: control | Intervention Type: OTHER; Name: virtual reality training; Assigned to Arm(s): VRT | Intervention Type: OTHER; Name: control; Assigned to Arm(s): control

Answer: D